Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 8Terminated 5Withdrawn 1

Sponsor Class

OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1

Interventions

Paclitaxel 31Cyclophosphamide 30Cisplatin 29Bevacizumab 28Carboplatin 27Fluorouracil 24pembrolizumab 21Nivolumab 21Leucovorin 20Rituximab 19avelumab 18Gemcitabine 18Docetaxel 18Dexamethasone 18Capecitabine 17ALT-803 15130-nm albumin-bound paclitaxel 14Oxaliplatin 12Cetuximab 12fludarabine 11Ipilimumab 11venetoclax 10atezolizumab 10Radiosurgery 10Radiotherapy 9Pemetrexed 9Omacor 9Lenalidomide 9Bendamustine Hydrochloride 9yeast-CEA vaccine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × INDUSTRY × ibritumomab tiuxetan × Clear all
NCT00319332 2015-04-17

A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen

GlaxoSmithKline

Phase 3 Withdrawn
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡